Background: Some syphilitic patients remain in a serologically positive state after the recommended therapy. Although we often retreat patients in clinical practice, the optimal treatment protocol remains uncertain due to the paucity of data regarding serological response to retreatment and long-term outcomes.
Introduction
Since the year 2000, the incidence of syphilis has been increasing in the UK, the USA, Canada, Europe and Australia. 1 In sub-Saharan Africa, it contributes to 20% of perinatal deaths. 2 During 2010, it caused 113000 deaths. 3 During the past three decades, China has been experiencing a syphilitic epidemic (Figure 1 ), showing a rise in incidence from 6.4 per 100000 in 2000 to 32.9 per 100000 in 2013. 4, 5 Now, syphilis has become the third most reported communicable disease in China. 6, 7 The current guidelines in both the USA 8 and the UK 9 recommend benzathine penicillin as first-line treatment for syphilis. However, not all cases achieve serological reversal after benzathine penicillin treatment; some cases show persistent reactive serological tests or fail to achieve serological cure, defined as a ,4-fold (2 dilution) decline in the rapid plasma reagin (RPR) serological test at 6-12 months, 8, 10, 11 which can be quite disconcerting for both the patient and the physician. 12 Although we often retreat patients in clinical practice, the optimal treatment protocol remains uncertain due to the paucity of data regarding serological response to retreatment and longterm outcomes. We conducted analyses of data to determine the serological response of serofast early syphilis cases after retreatment.
Methods

Patients
Data on clinical and laboratory-diagnosed syphilis cases were retrospectively analysed. All syphilitic patients were outpatients who visited the sexually transmitted disease (STD) centre of Peking Union Medical College Hospital, China, from January 2001 to January 2013. All cases were diagnosed as having various stages of syphilis according to the national CDC diagnostic standard. According to Chinese national guidelines, 13 primary syphilis is defined as a clinically compatible patient characterized by more than one chancre and inguinal lymphadenopathy, and laboratory confirmation of Treponema pallidum in clinical specimens by RPR and particle agglutination assay for antibody to Treponema pallidum (TPPA), or T. pallidum haemagglutination (TPHA), and/or fluorescent treponemal antibody absorption (FTA-ABS); secondary syphilis is defined as a clinically compatible patient characterized by skin rash and, in many patients, lymphadenopathy, and confirmation by laboratory testing results as for syphilis; and early latent syphilis is defined as an asymptomatic patient with a possible history of syphilitic infection supported by positive RPR and a positive treponemal test, and normal CSF. Clinicians from our STD centre ask for the possible infection time; 
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Treatment
According to Chinese national guidelines for the treatment of syphilis, 13 cases with early syphilis are treated with two or three doses of benzathine penicillin at 2.4 million units given intramuscularly each week. Alternatives to benzathine penicillin for the treatment of syphilis are 500 mg of erythromycin given orally four times per day for 2 weeks, 100 mg of doxycycline given orally twice per day for 2 weeks or 0.8 million units of procaine penicillin given intramuscularly per day for 10 days. After treatment, doctors reviewed the serum RPR titres and clinical symptoms of all patients every 3 months. The primary outcome was response to treatment, determined on the basis of changes in RPR titres at 6 months after therapy.
Seroreversion at 6 months following therapy was defined as becoming RPR negative after therapy. Serological cure was defined as either a negative RPR or a decrease of 2 dilutions (4-fold) in RPR titre. Serofast was defined as either no change in RPR titre or a 1 dilution (2-fold) decrease or increase in titre following initial therapy or retreatment. Subjects determined to be serofast at 6 months after initial therapy were included if they were retreated with three doses of benzathine penicillin, 2.4 million units given intramuscularly each week starting at the 6 month visit. Individuals were excluded if they were known to be HIV infected; the baseline serological test revealed a negative RPR test result (because our study was interested in serological response); they did not attend follow-up testing or follow-up testing was inadequate to determine the serological test result of treatment (i.e. ,6 months after retreatment); or they were confirmed to have CNS infection after CSF specimen examination. Cases for whom HIV status was not documented were not excluded as they were expected to constitute a small percentage of study cases, because the prevalence of HIV in our STD centre is low.
Statistical analysis
These analyses were performed on patients who were serofast at 6 months after initial treatment, received re-therapy and had serological test results at the 1 year visit. Proportions of subjects with seroreversion, serological cure or serofast status after retreatment were defined at 1 year using the definitions above. Subjects who achieved serological cure after retreatment and cases who remained serofast were compared for age and baseline and 6 month RPR titres using a Wilcoxon two-sample test, and were compared for sex, geometric mean RPR titres, initial treatment regimen and disease stage using a v 2 test. Statistical analysis was performed using the SPSS statistical package, version 19.0 (SPSS, Chicago, IL, USA).
Results
Data on 1266 patients with early syphilis were collected. Of the 1266 patients, 179 (14.1%) were serofast at 6 months. We identified 70 eligible subjects with early syphilis who were serofast at 6 months after initial therapy with benzathine penicillin (n " 52) or alternatives (n " 18). Study cases ranged in age from 21 to 58 years with a mean age of 32 years and a median age of 30 years and 45 (64.3%) cases were female. Patients of Han nationality comprised the majority of cases (n " 69, 98.6%). The majority consisted of persons with education up to secondary school (n " 41, 58.6%). Coinfection with other STDs was found in two patients (2.9%). Only 1 (1.4%) serofast subject had primary syphilis, 15 (21.4%) had secondary syphilis and 54 (77.1%) had early latent syphilis.
After retreatment with benzathine penicillin, 28 (40%) subjects exhibited a .4-fold decline in RPR titres from their 6 month titres and 42 (60%) remained serofast at 12 months. However, when serological response was determined relative to baseline titres before initial treatment, 34 (48.6%) patients had achieved serological cure and 36 (51.4%) were serofast. Of those with serological response following retreatment, 11 had seroreversion to a non-reactive RPR at the 1 year follow-up. Sex and age were not associated with likelihood of achieving serological cure Retreatment of serofast early syphilis JAC after retreatment (Table 1) . However, there were statistically significant differences in disease stage, initial treatment regimen and the baseline and 6 month RPR titres between cases with serological cure and serofast cases. The median baseline RPR titre among the former was 1:32 compared with the median baseline titre of 1:4 among serofast cases (P , 0.001). There were similar differences in RPR titres at the 6 month visit between groups; patients with serological cure had a higher median RPR titre prior to retreatment than did patients who remained serofast at the 1 year follow-up (Table 1) . Furthermore, geometric mean RPR titres were significantly different between cases with serological cure and serofast status at baseline and at 6 months ( Table 1) .
Discussion
After retreatment with 2.4 million units of benzathine penicillin weekly for 3 weeks, 48.6% of cases with early syphilis who failed to achieve serological cure at 6 months after initial treatment achieved serological cure at 12 months, which is much higher than in a similar study by Seña et al.
14 [27% (22/80)]. However, Seña et al.
14 provided only one dose of benzathine penicillin for retreatment, which may be the reason for the lower serological cure rate. Early syphilis cases who had higher RPR titres at baseline (1:32) and at 6 months (1:16) were more likely to exhibit serological cure after retreatment than those with lower RPR titres. In the similar study by Seña et al., 14 among the patients who were serofast at 6 months, only a small proportion (2/82) exhibited seroreversion after retreatment, whereas we reported a much higher proportion (11/70) exhibiting seroreversion after retreatment with 2.4 million units of benzathine penicillin weekly for 3 weeks. Thirty-three of our patients who were serofast at 6 months returned for additional follow-up at 2 years after initial therapy, showing a serological cure of 54.5% (18/33) when serological response was determined relative to baseline titres before initial treatment. The limitation of this study is the lack of a comparison group by which to determine the expected decline in nontreponemal titres among serofast cases in the absence of retreatment. Therefore, we cannot totally rule out that the serological cure/seroreversion shown by 54.5% of our cases may have been due to the natural decrease in RPR titres after initial therapy, rather than due to the additional three doses of benzathine penicillin.
Clinical management of syphilitic cases who are in a serologically active state after the recommended therapy is challenging. Further investigations are essential to elucidate the biological basis for the serofast status and to determine whether serofast cases should undergo continued serological monitoring, retreatment or CSF examination for T. pallidum involvement.
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